Kimball Electronics earnings date
Kimball Electronics (3C3) Q1 2027 Earnings Report
DE:3C3 Q1 2027 EPS Results
- Actual EPS
- EUR 0.23
- Consensus EPS
- EUR 0.36
- Beat/Miss
- Missed by -EUR 0.13
- One Year Ago EPS
- EUR 0.44
DE:3C3 Q1 2027 Revenue Results
- Actual Revenue
- EUR 352.18M
- Expected Revenue
- EUR 348.94M
- Beat/Miss
- Beat by +EUR 3.25M
- YoY Revenue Growth
- +6.89%
Earnings Announcement Details
- Quarter
- Q1 2027
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Kimball Electronics's next earnings date is estimated for February 8, 2027, based on past reporting schedules.
Q1 2027 Earnings Call Audio
Q1 2027 Earnings Slide Deck
Q1 2027 Earnings Call Summary
The call was overall constructive, supported by 7% year-over-year sales growth, strong medical performance, 16% open-order growth, planned Helvoet synergies, progress at the Indianapolis facility and reiterated full-year guidance at the high end of the sales range. However, profitability was pressured by higher material costs, the medical CDMO ramp, increased interest expense and a significantly higher tax rate, while Climate Control and North American Automotive remained challenged. The positive operating and strategic developments outweighed the stated financial and end-market pressures.
For fiscal 2027, Kimball Electronics reiterated guidance with sales expected at the high end of the range of $1.535 billion to $1.560 billion, adjusted operating income expected to be 4.4% to 4.7% of net sales, and capital expenditures in the range of $50 million to $60 million; the full fiscal year tax rate is expected to be in the low 30s when excluding the impact of the withholding taxes, Helvoet is tracking pretty much as expected in terms of that $60 million of revenue and contribution range, core medical is coming in stronger with double-digit growth expected, and production at the Indianapolis facility is expected to start in December.
- Sales Growth Across the CompanyFirst-quarter net sales were $390.8 million, up 7% year over year and 5% sequentially. Organic growth was 3%, Helvoet contributed $12.4 million of revenue, and foreign exchange had a 1% favorable impact on consolidated sales. Year-over-year growth occurred in all verticals.
- Medical Revenue Growth and Portfolio BalancingMedical sales were $116 million, up 14% year over year and representing 29% of total company sales. Broad-based organic growth increased 9%, with strength across drug delivery devices, respiratory care products, patient monitoring systems, single-use surgical instruments and imaging systems. Management said the growth was across geographies and driven partly by new launches.
- Industrial GrowthIndustrial sales were $105 million, up 5% year over year and representing 27% of total company sales. More than one-third of the increase came from organic growth, with strength in off-highway equipment, factory automation, public safety and smart metering.
- Automotive Growth Supported by Steering ProgramsAutomotive sales were $171 million, up 4% year over year and representing 44% of company sales. Steering drove the organic growth, accounted for over 70% of Automotive in the quarter, and benefited from the ramp-up of a new program in Poland and early preparations for a transfer of production in China.
- Healthy Cash Conversion and EBITDAManagement described margins as healthy, while cash conversion days were 82 days, equaling the multiyear best achieved in the prior quarter and improving by 1 day from the first quarter of fiscal 2026. Adjusted EBITDA was $27.6 million versus $26.7 million a year ago.
- Fiscal 2027 Guidance Reiterated at High End of Sales RangeThe company reiterated fiscal 2027 guidance, with sales expected at the high end of the $1.535 billion to $1.560 billion range. Adjusted operating income is expected to be 4.4% to 4.7% of net sales, and capital expenditures are expected to be $50 million to $60 million.
- Helvoet Integration Progressing as PlannedManagement said Helvoet integration is progressing on plan and on budget, with top-line synergies as the first priority. Customer interest is rising as the complementary capabilities of Tilburg, Pune, Indianapolis and the broader Kimball footprint become better understood. Helvoet is tracking as expected toward the stated $60 million revenue and contribution range.
- Investment in Medical CDMO GrowthThe company is integrating Helvoet, ramping operations in Indianapolis, leveraging its full-service capabilities and pursuing synergies across its global footprint. The enhanced medical CDMO platform has available capacity to support growth in multiple end-market applications.
- Indianapolis Facility on ScheduleThe transfer of operations in Indianapolis remains on schedule and on budget. Equipment and manufacturing lines are being moved, installed and qualified in a manner intended to ensure uninterrupted customer support, with production expected to start in December.
- Expanded Medical Business Development EffortsKimball expanded the responsibilities of Helvoet CEO Eveline Hogenkamp and her team and equipped them with AI-driven data-mining tools intended to identify real-time medical-market opportunities where the company's capabilities can provide near-term solutions.
- Strong Open-Order GrowthOpen orders grew 16% year over year to $690 million. Management said growth was across all geographies and programs and indicated that the 9% core medical growth in the quarter may be the lowest level seen during the fiscal year, while the company is looking at double-digit growth.
- Liquidity and Growth-Supporting Capital AllocationCash and cash equivalents were $72.8 million, while short-term liquidity totaled $270.8 million. First-quarter capital expenditures were $9 million, spread across the footprint to support future growth. The company also repurchased 127,000 shares for $3.1 million; since October 2015, it has returned $118.6 million to shareholders through purchases of 7.2 million shares.
- Strategic Rebranding InitiativeThe company is seeking shareholder support to rebrand the entire company as Kimball Solutions. If approved, the change would occur at the end of the fiscal year and reflect an expanded portfolio that includes design and engineering support, supply chain management, precision molded plastics and high-level product assemblies.
DE:3C3 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 08, 2027 | 2027 (Q2) | 0.32- | 0.25 | ― | ― |
| Nov 04, 2026 | 2027 (Q1) | 0.360.23 | 0.44 | -48.98% (-0.22) | |
| Aug 12, 2026 | 2026 (Q4) | 0.35-0.01 | 0.31 | -102.94% (-0.32) | |
| May 05, 2026 | 2026 (Q3) | 0.300.30 | 0.24 | 22.22% (+0.05) | |
| Feb 04, 2026 | 2026 (Q2) | 0.230.25 | 0.26 | -3.45% (-0.01) | |
| Nov 05, 2025 | 2026 (Q1) | 0.230.44 | 0.2 | 122.73% (+0.24) | |
| Aug 13, 2025 | 2025 (Q4) | 0.170.31 | 0.3 | 3.03% (+0.01) | |
| May 06, 2025 | 2025 (Q3) | 0.150.24 | 0.31 | -20.59% (-0.06) | |
| Feb 04, 2025 | 2025 (Q2) | 0.180.26 | 0.3 | -12.12% (-0.04) | |
| Nov 04, 2024 | 2025 (Q1) | 0.230.20 | 0.38 | -47.87% (-0.18) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
